Ex-vivo liver perfusion for organ preservation: Recent advances in the field
Liver transplantation is the optimal treatment for end-stage liver disease but is limited by the severe shortage of donor organs. This shortage has prompted increased utilization of marginal grafts from DCD and extended criteria donors, which poorly tolerate cold storage in comparison to standard criteria grafts. Ex-vivo liver perfusion (EVLP) technology has emerged as a potential alternative to cold storage for organ preservation, but there is no consensus regarding the optimal temperature or conditions for EVLP. (Source: Transplantation Reviews)
Source: Transplantation Reviews - April 14, 2016 Category: Transplant Surgery Authors: A.S. Barbas, N. Goldaracena, M.J. Dib, M. Selzner Source Type: research
Management of cytomegalovirus infection in solid organ transplant recipients: SET/GESITRA-SEIMC/REIPI recommendations
Cytomegalovirus (CMV) infection remains a major complication of solid organ transplantation. Because of management of CMV is variable among transplant centers, in 2011 the Spanish Transplantation Infection Study Group (GESITRA) of the Spanish Society of Infectious Diseases and Clinical Microbiology (SEIMC) developed consensus guidelines for the prevention and treatment of CMV infection in solid organ transplant recipients. Since then, new publications have clarified or questioned the aspects covered in the previous document. (Source: Transplantation Reviews)
Source: Transplantation Reviews - April 14, 2016 Category: Transplant Surgery Authors: J. Torre-Cisneros, J.M. Aguado, J.J. Caston, L. Almenar, A. Alonso, S. Cantisán, J. Carratalá, C. Cervera, E. Cordero, M.C. Fariñas, M. Fernández-Ruiz, J. Fortún, E. Frauca, J. Gavaldá, D. Hernández, I. Herrero, O. Len, F. Lopez-Medrano, N. Manito, Source Type: research
Serologic and molecular biomarkers for recurrence of hepatocellular carcinoma after liver transplantation: A systematic review and meta-analysis
Recurrence after liver transplantation (LT) for hepatocellular carcinoma (HCC) is a major cause of mortality. Knowledge on biomarkers may contribute to better surveillance based on the patients' risk of recurrence. Reviewing the literature, we aimed to identify serological and molecular biomarkers for recurrence of hepatocellular carcinoma after liver transplantation. (Source: Transplantation Reviews)
Source: Transplantation Reviews - April 7, 2016 Category: Transplant Surgery Authors: Hans-Christian Pommergaard, Jakob Burcharth, Jacob Rosenberg, Allan Rasmussen Source Type: research
Serologic and molecular biomarkers for recurrence of hepatocellular carcinoma after liver transplantation: a systematic review and meta-analysis
Recurrence after liver transplantation (LT) for hepatocellular carcinoma (HCC) is a major cause of mortality. Knowledge on biomarkers may contribute to better surveillance based on the patients’ risk of recurrence. Reviewing the literature, we aimed to identify serological and molecular biomarkers for recurrence of hepatocellular carcinoma after liver transplantation. (Source: Transplantation Reviews)
Source: Transplantation Reviews - April 7, 2016 Category: Transplant Surgery Authors: Hans-Christian Pommergaard, Jakob Burcharth, Jacob Rosenberg, Allan Rasmussen Source Type: research
Subscription prices
(Source: Transplantation Reviews)
Source: Transplantation Reviews - March 31, 2016 Category: Transplant Surgery Source Type: research
Editorial Board
(Source: Transplantation Reviews)
Source: Transplantation Reviews - March 31, 2016 Category: Transplant Surgery Source Type: research
Table of Contents
(Source: Transplantation Reviews)
Source: Transplantation Reviews - March 31, 2016 Category: Transplant Surgery Source Type: research
Instructions for Authors
(Source: Transplantation Reviews)
Source: Transplantation Reviews - March 31, 2016 Category: Transplant Surgery Source Type: research
Previous Issue
(Source: Transplantation Reviews)
Source: Transplantation Reviews - March 31, 2016 Category: Transplant Surgery Source Type: research
Use of everolimus in liver transplantation: The French experience
The mammalian target of rapamycin (mTOR) inhibitor everolimus is approved for rejection prophylaxis after liver transplantation. The current article pools the experience of French liver transplant surgeons and physicians in use of everolimus and, particularly, practical guidance on dosing, appropriate concomitant immunosuppression and management of adverse events. In terms of indication, introduction of everolimus from week 4 after liver transplantation, with or without concomitant calcineurin inhibitor (CNI) therapy, offers a significant renal benefit without loss of immunosuppressive efficacy. (Source: Transplantation Reviews)
Source: Transplantation Reviews - March 19, 2016 Category: Transplant Surgery Authors: Jérôme Dumortier, Sebastien Dharancy, Yvon Calmus, Christophe Duvoux, François Durand, Ephrem Salamé, Faouzi Saliba Source Type: research
Statin therapy in cardiac allograft vasculopathy progression in heart Transplant patients: Does potency matter?
Cardiac allograft vasculopathy (CAV) is a unique pathologic process commonly encountered in heart transplant patients. Despite advances in maintenance immunosuppressive regimens and continuously evolving strategies for the detection and treatment of cellular and antibody-mediated rejection, CAV continues to be a limiting factor for long-term graft survival. The use of statin therapy for CAV has become standard of care based on numerous clinical studies demonstrating reduction in rejection and improved mortality. (Source: Transplantation Reviews)
Source: Transplantation Reviews - March 19, 2016 Category: Transplant Surgery Authors: Adam Sieg, Phillip Weeks, Lori Krustchinsky, Indranee Rajapreyar Source Type: research
Use of everolimus in liver transplantation: The French experience
The mammalian target of rapamycin (mTOR) inhibitor everolimus is approved for rejection prophylaxis after liver transplantation. The current article pools the experience of French liver transplant surgeons and physicians in use of everolimus and, particularly, practical guidance on dosing, appropriate concomitant immunosuppression and management of adverse events. In terms of indication, introduction of everolimus from week 4 after liver transplantation, with or without concomitant calcineurin inhibitor (CNI) therapy, offers a significant renal benefit without loss of immunosuppressive efficacy. (Source: Transplantation Reviews)
Source: Transplantation Reviews - March 18, 2016 Category: Transplant Surgery Authors: J érôme Dumortier, Sebastien Dharancy, Yvon Calmus, Christophe Duvoux, François Durand, Ephrem Salamé, Faouzi Saliba Source Type: research
Statin therapy in cardiac allograft vasculopathy progression in heart transplant patients: Does potency matter?
Cardiac allograft vasculopathy (CAV) is a unique multi-factorial pathologic process encountered following heart transplantation. Several risk factors have been identified including a combination of immunologic and non-immunologic processes. Significant research has been conducted to elucidate the driving forces of CAV as well as improved identification, prevention and treatment strategies. Statin therapy following transplant remains the standard of care to help prevent the progression of CAV. The benefits of statin therapy following transplantation correspond to cholesterol control, anti-inflammatory and immunomodulatory m...
Source: Transplantation Reviews - March 18, 2016 Category: Transplant Surgery Authors: Adam Sieg, Phillip Weeks, Lori Krustchinsky, Indranee Rajapreyar Source Type: research
Systematic literature review on self-reported quality of life in adult intestinal transplantation
Quality of life (QoL) gains importance in intestinal transplantation (ITx). This systematic review aimed to summarize all evidence on self-reported QoL in adult ITx. Pubmed, EMBASE, CCTR, CINAHL, PsycINFO were searched until October 2014. Structured data abstraction was performed and methodological quality was assessed using a standardized checklist. Nine eligible studies were identified addressing one or more study-aims: (i) QoL comparison pre- and post-ITx (n=4); (ii) QoL follow-up post-ITx (n=1); (iii) QoL comparison between ITx and home parenteral nutrition (HPN) patients (n=6), healthy subjects (n=1), general populati...
Source: Transplantation Reviews - February 23, 2016 Category: Transplant Surgery Authors: Laurens J. Ceulemans, Céline Lomme, Jacques Pirenne, Sabina De Geest Source Type: research
Rabbit antithymocyte globulin and donor-specific antibodies in kidney transplantation — A review
The mode of action of rabbit antithymocyte globulin (rATG) includes preferential inhibition of pre-existing donor-reactive memory T-cell reconstitution and possibly apoptosis of plasma cells, the source of donor specific antibodies (DSAs). In kidney transplant patients with low-strength preformed DSAs, non-comparative data have shown a low incidence of antibody-mediated rejection (ABMR) and graft survival using rATG even without desensitization procedures. For high strengths of preformed DSAs, rATG induction with more aggressive desensitization appears effective, with mixed results concerning the addition of B-cell specifi...
Source: Transplantation Reviews - February 18, 2016 Category: Transplant Surgery Authors: Julio Pascual, Andreas Zuckermann, Arjang Djamali, Alexandre Hertig, Maarten Naesens Source Type: research
